Therapeutic Monitoring, the Concentration-Effect Relationship and Impact on the Clinical Efficacy of Antibiotic Agents

REFERENCES

• Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamie model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-1060.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Vinks AATMM. Is continuous infusion of ß-lactam antibiotics worthwhile? - Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38: 5-15.
   PubMed Web of Science ®Google Scholar
• Jackson GG, Riff LJ. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis 1971; 124 suppl: S185-S191.
   PubMedGoogle Scholar
• Noone P, Parsons TMC, Pattison JR, Slack RCB, Garfield-Davies D, Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974; 1: 477-481.
   PubMed Web of Science ®Google Scholar
• Noone P, Pattison JR. The effective use of gentamicin in life-threatening sepsis. Postgrad Med J 1974; 50 suppl. 7: 9-16.
   PubMedGoogle Scholar
• Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149: 443-448.
   PubMed Web of Science ®Google Scholar
• Noone P, Rogers BT. Pneumonia caused by coliforms and Pseudomonas aeruginosa. J Clin Pathol 1976; 29: 652-656.
   PubMed Web of Science ®Google Scholar
• Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657-662.
   PubMed Web of Science ®Google Scholar
• Reymann MT, Bradac JA, Cobbs CG, Dismukes WE. Correlation of aminoglycoside dosages with serum concentrations during therapy of serious Gram-negative bacillary disease. Antimicrob Agents Chemother 1979; 16: 353-361.
   PubMed Web of Science ®Google Scholar
• Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. Br Med J 1996; 312: 338-345.
   PubMed Web of Science ®Google Scholar
• Blaser J, König C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol infect Dis 1995; 14: 1029-1038.
   PubMed Web of Science ®Google Scholar
• Blaser J, Simmen HP, Thurnheer U, König C, Luthy R. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother 1995; 36: 803-814.
   PubMed Web of Science ®Google Scholar
• Working party of the British Society for Antimicrobial Chemotherapy. Antibiotic treatment of streptococcal and staphylococcal endocarditis. Lancet 1985; 2: 815-817.
   PubMed Web of Science ®Google Scholar
• Drusano GL. Pharmacology of anti-infective agents. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:231.
   Google Scholar
• Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
   PubMed Web of Science ®Google Scholar
• Schentag JJ. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Scand J Infect Dis 1991; suppl. 74: 218-234.
   Google Scholar
• Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in breakthrough gram-negative rod bacteraemia. Am J Med 1976; 61: 493-497.
   PubMed Web of Science ®Google Scholar
• Roosendaal R, Bakker-Woudenberg IAJM, Van den Berghe- van Raffe M, Michel MF. Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrob Agents Chemother 1986; 30: 403-408.
   PubMed Web of Science ®Google Scholar
• Roosendaal R, Bakker-Woudenberg IAJM, Van den Berg JC, Michel MF. Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. J Infect Dis 1985; 152: 373-378.
   PubMed Web of Science ®Google Scholar
• Gerber AU, Craig WA, Brugger H-P, Feller C, Vastola AP, Brandei J. Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis 1983; 147: 910-917.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Ketchel SJ, Rodriguez V. A randomised study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67: 608-616.
   PubMed Web of Science ®Google Scholar
• Jones BL, Ludlam HA, Brown DFJ. High dose ampicillin for the treatment of high-level aminoglycoside resistant enterococcal endocarditis. I Antimicrob Chemother 1994; 33: 891-892.
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-490.
   PubMed Web of Science ®Google Scholar
• Bauernfeind A. Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 1993; 31: 789-798.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Cumbo TJ, Nix DE, Sands ME, Schentag JJ. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Arch Intern Med 1989; 149: 2269-2273.
   PubMedGoogle Scholar
• Kljucar S, Heimesaat M, Von Pritzbuer E, Timm J. Efficacy and safety of higher-dose intravenous ciprofloxacin in severe hospital-acquired infections. Am J Med 1989;87 suppl. 5A: S52-S56.
   Google Scholar
• ABPI data sheet compendium 1996-1997.
   Google Scholar
• Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995; 36: 279-282.
   PubMed Web of Science ®Google Scholar
• Catchpole C, Hastings JGM. Measuring pre- and postdose vancomycin levels - time for a change? J Med Microbiol 1995;45:309-311.
   Google Scholar
• Cafferkey MT, Hone R, Keane CT. Severe staphylococcal infections treated with vancomycin. J Antimicrob Chemother 1982; 9: 69-74.
   PubMed Web of Science ®Google Scholar
• Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for metbicillin-resistant Staphylococcus aureus. Ann Intern Med 1982; 97: 344-350.
   PubMed Web of Science ®Google Scholar
• Besnier JM, Leport C, Bure A, Vilde JL. Vancomycin-aminoglycoside combinations in therapy of endocarditis caused by Enterococcus species and Streptococcus bovis. Eur J Clin Microbiol Infect Dis 1990; 9: 130-133.
   PubMed Web of Science ®Google Scholar
• Smith SR, Cheesbrough J, Spearing R, Davies JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 1989; 33: 1193-1197.
   PubMed Web of Science ®Google Scholar
• Flandrois JP, Fardel G, Carret G. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother 1988; 32: 454-457.
   PubMed Web of Science ®Google Scholar
• Ackerman BH, Vannier AM, Eudy EB. Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response. Antimicrob Agents Chemother 1992; 36: 1766-1769.
   PubMed Web of Science ®Google Scholar
• Peetermans WE, Hoogeterp JJ. Hazekamp-van Dokkum A-M, Vand den Broek P, Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990; 34: 1869-1874.
   PubMed Web of Science ®Google Scholar
• Saunders NT. Why monitor peak vancomycin concentrations? Lancet 1994; 344: 1748-1750.
   PubMed Web of Science ®Google Scholar
• Mulhern JG, Braden GL, O'Shea MH, Madden RL, Lipkowitz GS, Germain MJ. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995; 25: 611-615.
   PubMed Web of Science ®Google Scholar
• Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990; 34: 510-514.
   PubMed Web of Science ®Google Scholar
• Martino P, Venditti M, Micozzi A, Brandimarte C, Gentile G, Santini C, Serra P. Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother 1989; 33: 1329-1334.
   PubMed Web of Science ®Google Scholar
• Gilbert DN, Wood CA, Kimbrough RC, and the Infectious Diseases Consortium of Oregon. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991; 35: 79-87.
   PubMed Web of Science ®Google Scholar
• Galanakis N, Giamarellou H, Vlachogiannis N, Dendrinos C, Daikos GK. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. Eur J Clin Microbiol Infect Dis 1988; 7: 130-134.
   PubMed Web of Science ®Google Scholar
• Wilson APR, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; suppl. 4: S1-S30.
   Google Scholar
• MacGowan A, White L, Reeves D, Harding I. A retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. In press - Journal of Infection and Chemotherapy.
   Google Scholar
• Reeves DS, MacGowan AP, Holt HA, Lovering AM, Warnock DW, White LC. Therapeutic monitoring of antimicrobials: a summary of the information presented at the UK NEQAS for antibiotic assays meeting for participants, October 1993. J Antimicrob Chemother 1995; 35: 213-226.
   PubMed Web of Science ®Google Scholar
• Greenberg RN. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990; 34: 2392-2397
   PubMed Web of Science ®Google Scholar
• Lau WK, Young LS. Trimethoprim-sulfamethoxazole treatment of Pneumocystis carinii pneumonia in adults. N Engl J Med 1976; 295: 716-718.
   PubMed Web of Science ®Google Scholar
• Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trfmethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1988; 109: 280-287.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980; 92: 762-769.
   PubMed Web of Science ®Google Scholar
• Joos B, Blaser J, Opravil M, Chave J-P, Luthy R. Monitoring of co-trimoxazole concentrations in serum during treatment of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1995; 39: 2661-2666.
   PubMed Web of Science ®Google Scholar
• MacGowan A. Concentration controlled and concentration defined clinical trials: do they offer any advantages for antimicrobial chemotherapy? J Antimicrob Chemother 1996; 37: 1-5.
   PubMed Web of Science ®Google Scholar